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Our pilot study indicates that mentalization-based
treatment may be a promising treatment modality for
female patients with comorbid substance use disorder
and borderline personality disorder, write Katharina
T. E. Morken and colleagues.
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One possible way of understanding substance use is by seeing it as
one of several self-soothing strategies utilized by patients who
struggle with personality problems (e.g., emotional dysregulation
and social deficiencies) (Philips, Kahn, & Bateman, 2012).
Substance use disorder (SUD) and personality disorder (PD) are
frequently co-occurring but clinically their comorbidity is often
ignored or treated separately; in some institutions, SUD is even
considered an exclusion criterion in treatment programs for PD.
There is no doubt that the comorbidity between personality disorder
and substance use disorder overall is high. Numerous studies have
demonstrated the frequent covariance between these two disorders
(Cacciola, Alterman, Rutherford, McKay, & Mulvaney, 2001; Fenton
et al., 2012; Hasin & Kilcoyne, 2012; McGlashan et al., 2000;
Thomas, Melchert, & Banken, 1999; Trull, Jahng, Tomko, Wood, &
Sher, 2010; Verheul, 2001). It has been debated whether it is PD in
general or Cluster B specifically that drives the covariation. It has
also been discussed if the covariance can be explained by
overlapping criteria (e.g., impulsivity in borderline personality
disorder (BPD) and antisocial PD).
For example, in one study of opiate use disorders in the National
Epidemiologic Survey on Alcohol and Related Conditions
(NESARC), 50% of respondents had a PD. When controlling for the
general criteria for PD, borderline personality disorder became a
clear predictor for SUD (Jahng et al., 2011). It has been suggested
that the covariation between BPD and SUD are linked via impulsivity
(Jahng et al., 2011; McGlashan et al., 2000). Among SUD patients,
a median of 57% (range 35%–73%) had concurrent PD (Verheul,
2001), and among PD in the general population, the prevalence of
comorbid SUD was 42% for alcohol and 19% for substance use
(Trull et al., 2010).
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In Scandinavian samples, the co-occurrence of SUD in PD in a
population-based study was 46% (Toftdahl, Nordentoft, & Hjorthøj,
2016). For female patients with SUD, BPD is the most common
personality disorder (Landheim, Bakken, & Vaglum, 2003). Cluster B
personality traits have been found to be independent risk factors for
developing SUD (Cohen, Chen, Crawford, Brook, & Gordon, 2007;
Walter et al., 2009). BPD has been found as a significant risk factor
for the persistence of SUD (Fenton et al., 2012), but remission of
SUD in BPD in a 10-year study was also common (Zanarini et al.,
2011). Treatment of patients with BPD/SUD has been described as
difficult due to high dropout rates and to relational problems that
make the process of establishing a therapeutic alliance challenging
(Karterud, Arefjord, Andresen, & Pedersen, 2009).
For instance, Cluster B traits present a barrier in forming a
therapeutic alliance with SUD patients and Cluster B traits have been
found to provoke distanced and overwhelmed/disorganized
countertransference in helpers (Betan, Heim, Conklin, & Westen,
2005; Olesek et al., 2016; Thylstrup & Hesse, 2008). Concurrent
PD/SUD results in a more serious substance use disorder and more
substance use–related problems (Vélez-Moreno et al., 2016). Risk
for suicide attempts is higher for BPD patients with comorbid SUD
compared to BPD or SUD patients alone (Darke, Williamson, Ross,
Teesson, & Lynskey, 2004; Yen et al., 2003), although one study
found no correlation between suicide attempts and baseline PD
(Bakken & Vaglum, 2007). Risk for treatment attrition is higher for
PD/SUD compared to SUD alone (Ball, Carroll, Canning-Ball, &
Rounsaville, 2006; Brorson, Arnevik, Rand-Hendriksen, & Duckert,
2013; Cacciola et al., 2001). In addition, Cluster B traits and a PD
diagnosis have been found to influence outcome negatively for SUD
patients (Marlowe, Kirby, Festinger, Husband, & Platt, 1997;
Thomas et al., 1999), although in one study PD had no influence on
the outcome of SUD at a six-year follow-up (Landheim, Bakken, &
Vaglum, 2006).
Thus, when BPD and SUD co-occur, the patients seem to be
struggling even more than when each of these serious disorders
occurs alone, and therapeutically there are many pitfalls. Patients
with dual diagnoses are marginalized, often excluded from
psychiatric treatments, and most likely need additional support
(Toftdahl, Nordentoft, & Hjorthøj, 2016). Many have voiced the need
for targeted treatments for this group of patients (Hesse & Fridell,
2009; Ravndal, Vaglum, & Lauritzen, 2005; Vélez-Moreno et al.,
2016).
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Concerning evidence for efficacy of psychotherapy for BPD/SUD,
the latest review found 10 controlled studies on BPD/SUD patients
(Lee, Cameron, & Jenner, 2015). The studies included four studies
with dialectical behavioral therapy (DBT), three with dual focused
schema therapy (DFST), and three with dynamic deconstructive
psychotherapy (DDP). DBT and DDP showed some reduction in
symptoms and substance use while DFST had minimal effect on
outcome. The authors conclude that the evidence base for treatment
of co-occurring BPD/SUD needs more research and that some
preliminary evidence exists to date in benefit of DBT and DDP.
Mentalization-based treatment has shown great promise with BPD
patients in various RCTs and naturalistic cohort studies, both within
the original environment (Bateman & Fonagy, 2001, 2009; Rossouw
& Fonagy, 2012) and from other independent institutions (Bales et
al., 2014; Bales et al., 2012; Jørgensen et al., 2014; Kvarstein et al.,
2015). In some studies (Bateman & Fonagy, 2009; Jørgensen et al.,
2013), the difference between the control condition (structured
clinical management, supportive group psychotherapy) and MBT has
not been that large regarding outcome. However, the superiority of
MBT has been demonstrated when the severity of PD is taken into
consideration (Bateman & Fonagy, 2013).
To date, there is only one unpublished study from Stockholm on
MBT for BPD/SUD. In this RCT, patients received 18 months of
MBT or treatment as usual (TAU) within an outpatient addiction
treatment clinic. Surprisingly, the MBT patients (N=24) did not differ
from the control group (N = 22) with respect to outcome. There was
one near significant finding (Mann-Whitney p = 0.06) that
demonstrated the MBT group had no suicide attempts during
treatment, versus four in the control group (Philips, 2016). However,
we cannot know for sure that treatment in this study was MBT proper
since adherence was low (Karterud & Bateman, 2010; Möller,
Karlgren, Sandell, Falkenström, & Philips, 2016; Philips, 2016).
Another study on MBT with severely impaired young BPD patients
involved 79% with comorbid SUD. In this study, MBT showed
improvement on several outcome measures, and effect sizes were
large (Bales et al., 2012).
Thus, to date, we still do not know whether MBT is an efficient
approach for BPD/SUD patients. It could be that the presence of
SUD has some consequences for treatment that we still do not fully
understand. We have tentative knowledge that BPD/SUD patients
seem to improve after MBT, but we also have knowledge of the
opposite: no improvement at all. Many have advocated the
importance of tailoring treatments to these patients who are so
severely disordered. Still, we have only preliminary evidence that
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specialized treatment (e.g., DBT) for this patient group is beneficial
(Lee et al., 2015). Against this backdrop, we aimed to investigate in
a pilot project if MBT, a specialized tailored treatment for BPD, is
promising in the treatment of a group of severely disordered dual
diagnosis patients with BPD/SUD. Furthermore, we strove to
investigate the feasibility aspects of implementation, delivery by
clinicians, and acceptability for patients in order to clarify whether a
larger study could be recommended on this population and within
this context. 
Research questions
Does mentalization-based treatment have any positive effect on
BPD/SUD patients’ substance use and personality disorder (primary
outcome)? Does mentalization-based treatment have any positive
effect on symptom distress and/or interpersonal and social
functioning (secondary outcome)? Is MBT feasible as a treatment
and for investigation in a larger study format in a general drug clinic
on female patients with dual PD/SUD?
Material and Methods
Subjects
Patients were recruited from the inpatient and outpatient facilities of
the Bergen Clinic Foundation (BCF). Patients in the BCF consist of
both inpatients and outpatients with SUD, the majority with alcohol
use disorder (40%–45%) and then equally distributed SUD diagnosis
among cannabis, benzodiazepines and amphetamine dependency
as most frequent. Multiple substance use is common; most patients
have more than one SUD diagnosis. Most patients are without
occupation (78%) and supported by different economic welfare
benefits (75%–80%). A minority of the patients are female (27%)
(Skutle, 2017). Because the BCF has an explicit focus on gender-
specific treatment where males and females are given separate
treatments, this pilot was performed with female patients alone. We
went out broadly in the clinic asking for participants who were
“difficult to treat,” female, and with a tentative diagnosis of BPD.
Eighteen patients were included in the project. Inclusion criteria
included being female and having a diagnosis of SUD together with
a personality disorder with clinically significant borderline traits
according to the SCID-II (Gibbon, Spitzer, & First, 1997). The full
diagnosis of BPD was not necessary to enter the pilot. Exclusion
criteria were diagnosis of schizophrenia and substitute opiate
medication. See Table 2 for diagnostic profiles.
The patients were severely impaired, and all had histories of trauma.
Seven of 18 had histories with rape, eight had been victims of
violence in childhood, 10 had a history of neglect in childhood, and
seven had experienced sexual trauma in childhood. Most patients
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had problems with violence and aggression. Ten of 18 had been
violent toward people, 14 of 18 had been violent to material objects,
and seven of 18 had been reported to the police for violent offences.
Six patients had a prior history of psychotic episodes but not a
diagnosis of schizophrenia. Their history of prior treatment was quite
substantial, with a mean of four (range 1–15) prior admissions to
inpatient treatment and a mean of three (range 1–7) periods of
outpatient treatment.
They had a mean of two (range 1–4) SUD diagnoses and a mean of
four (range 1–7) Axis I diagnoses at baseline. (See Table 2 for
diagnostic characteristics.) All patients had maladaptive traits within
the BPD category (range 3–9 traits). As for PD traits according to
SCID-II, they had a mean of 18 (range 9–42) PD traits. The
distribution of PDs can be seen in Table 3. Nine patients had more
than one PD (range 2–5 PDs).
Clinical vignettes on one patient are hereby included to demonstrate
a typical patient in this project:
Patient 1
Female patient, 28 years old, antisocial PD/BPD, polysubstance use
disorder, and ADHD. History of neglect and conduct disorder in
childhood. Before treatment, she uses amphetamine daily
intravenously and in addition opiates and benzodiazepines. During
assessment, she gets an ADHD diagnosis and starts on appropriate
medication. Her level of functioning is very low, with a GAF score of
37. She has frequent impulsive, aggressive outbursts with people
around her, both strangers and close relations. She gets easily
agitated and sometimes uses violence or threats of violence. She is
unemployed and receives welfare benefits. She finished two years of
MBT. At follow-up she describes being abstinent from all drugs for
the last four years. She has much fewer conflicts with others
because she is able to see situations from the other’s perspective.
She has started a part-time job and deals with the relational aspect
of working by thinking things through instead of acting out on
colleagues. She is very grateful for the treatment that helped her.
Patients were assessed prior to treatment, every six months during
treatment, and at follow-up. The number of measurement points per
patient varied with a mean of four (range 2–6). All patients were
invited via post to participate in a follow-up assessment. They
received a gift certificate of 500 NOK (60 Euro / 60 U.S. dollars) for
participation. Thirteen patients participated. Five patients did not
participate in the follow-up. Some descriptive data and length of
treatment are included below. Their reasons for not participating in
the follow-up were: 1) One patient threatened suicide if we ever
contacted her again (13 months MBT); 2) one patient was of
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unknown whereabouts in another continent, and her family had no
idea where and when she would be back (10 months MBT); 3) one
patient angrily said no and hung up the telephone (six months MBT);
4) one patient agreed to come to follow-up but never showed up, and
she never answered our requests again (one month MBT); 5) one
patient was severely ill after a drug-related incident and was
chronically hospitalized and unable to perform assessment (seven
months MBT). Thus, compared to follow-up attenders, the mean
duration of treatment was lower (seven vs. 22 months).
Follow-up assessments were performed at a mean of 22 ( SD = 18)
months after termination of MBT. In the follow-up, the pre-treatment
battery was repeated together with qualitative interviews.
FIGURE 1: Patient flow in 36 months of MBT and follow-up at 22 months post-
treatment.
TABLE 1: Demographic characteristics of patients at baseline (N =
18).
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TABLE 2: Clinical characteristics of patients at baseline (N = 18).
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TABLE 3: Personality disorders at baseline (N = 18).
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Dual focus mentalization-based treatment
Training in MBT consisted of a three-day introductory course and a
one-year specialization course (eight days). In addition, therapists
received weekly video supervision with an expert in MBT and
monthly video supervision with an external supervisor, also expert in
MBT. Treatment was performed according to group and individual
manuals (Karterud, 2011, 2012; Karterud & Bateman, 2010).
Adherence was not measured, but weekly video supervision was
conducted according to the manuals. Patients started out with 12
sessions of MBT psychoeducation and then continued with the
group (MBT-G) and individual therapy (MBT-I). Maximal treatment
duration was three years and involved weekly individual and group
sessions throughout the entire period. Mean months in treatment
were 22 (SD = 15). In dual focus MBT, focus on the mental function
of SUD is of importance. Incidents of substance use are considered
important and the focus is on exploring the mentalizing failure and
interpersonal context prior to intake. All patients had access to a
social counselor who was trained in MBT and who attended the
supervisory sessions. The task of the social counselor was to offer
help with social functioning in addition to increasing mentalization
both there and then subsequently in encounters with the social
welfare system, child protective services, and the like. The social
counselor also did a thorough mapping of the patients’ social,
economic, and work status and offered help with attaining their goals
in social and work functioning.
Diagnostics
All therapists were trained in GAF and SCID-II assessments from a
supervisor from the Norwegian Network of Personality-Focused
Treatment Programs, and the assessment procedures were equal to
those used by this network. (See for instance Kvarstein et al., 2015).
Diagnostic reliability was not measured, but therapists were specially
trained in the diagnostics of PD, and diagnoses were discussed
thoroughly within the team and with the supervisor. In addition,
according to the LEAD principle, diagnoses were open for
adjustments during the clinical trajectory (Spitzer, 1983). At follow-
up, diagnostics were performed by the first and fourth authors, who
together evaluated SCID, GAF, and MINI diagnosis of all patients.
Both also performed the diagnostic interviews.
Outcome measures
Axis I SUD diagnosis
Patients were interviewed with the Mini-International
Neuropsychiatric Interview-Plus (M.I.N.I-Plus) before treatment and
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at follow-up (Sheehan et al., 1998). M.I.N.I-Plus is a structured
diagnostic interview covering the most prevalent Axis I disorders
within both DSM-IV and ICD-10.
Axis II disorders
Patients were diagnosed on Axis II by clinical interviews before
treatment and at follow-up according to the Structured Clinical
Interview for DSM-IV (SCID-II) (Gibbon et al., 1997). Following the
LEAD principle, some of the diagnoses were revised after further
clinical observation during the treatment period (Spitzer, 1983). The
SCID-II is a semi-structured 94-item clinical interview that
investigates the presence of PD according to the criteria from DSM-
IV. Questions are answered with a yes or no and then further
investigated through probing for examples. The interviewer decides
if a patient fulfills criteria on SCID-II based on all available clinical
information in addition to answers given during the interview.
SCL-90-R symptom distress
Symptoms were measured with SCL-90-R (Derogatis, 1977). The
General Severity Index (GSI) is a well-known symptom distress
measure and is widely used within clinical psychotherapy research.
GSI gives a broad picture of a patient’s symptom distress in general.
It is an average score of the total 90 items. The clinical/non-clinical
cutoff level is set at GSI = 0.8 for women based on a Norwegian
patient sample (Pedersen & Karterud, 2004). Cronbach’s alpha at
baseline = 0.89.
Interpersonal functioning
Interpersonal functioning was measured as the Circumplex of
Interpersonal Problems (CIP) (Pedersen, 2002), which is a
Norwegian short version of the IIP-C (Horowitz, Rosenberg, Baer,
Ureño, & Villaseñor, 1988). The mean sum score (CIP) correlates
highly (r = 0.99) with the original IIP-C sum score (Pedersen, 2002).
The clinical cutoff score of CIP is 0.8 (i.e., one standard deviation
above mean IIP sum scores (M = 0.53) in a non-clinical Norwegian
population) (Kvarstein et al., 2015; Pedersen, 2002). CIP has 48
items with a five-point scale, where subjects rate the degree of
interpersonal problems. The CIP sum score is an indicator of the
general level of experienced interpersonal problems and is based on
a mean average of all 48 items. Cronbach’s alpha at baseline =
0.56.
Global assessment of functioning
The Global Assessment of Functioning (GAF) scale (Hall, 1995) is a
widely used rating scale, ranging from 0 to 100, where 100
represents maximal global functioning (Pedersen & Karterud, 2012).
GAF has shown high reliability between experienced judges and is a
quick and easy instrument that can be used for measuring an
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individual patient’s need for treatment and at which level of health
care (Pedersen, Hagtvet, & Karterud, 2007). A score of 60 indicates
mild symptoms or impairment and is considered a good cutoff
indicator for functional impairment in studies with treatment of PD
(Kvarstein & Karterud, 2012).
Self-esteem
The Rosenberg Self-Esteem Scale (RSES) is a 10-item self-report
questionnaire (Rosenberg, 1986). The 10 items are rated on a four-
point scale from “strongly disagree” (1) to “strongly agree” (4). Cutoff
for “normal” self-esteem lies at 3 (+/– 0.4). According to one study
across 53 nations, RSES has good internal consistency with a mean
Cronbach’s alpha coefficient reported of 0.81 (Schmitt & Allik, 2005).
In the current study, Cronbach’s alpha at baseline was 0.89.
Work and social functioning scale 
The Work and Social Adjustment Scale (WSAS) is a five-item self-
report questionnaire (Mundt, Marks, Shear, & Greist, 2002). The five
items are rated on an eight-point scale from “not impaired at all” to
“severely impaired,” the responses to which are based on the last
four weeks of functioning. The scoring range goes from 0 to 40,
where a score above 20 represents severe psychopathology and
functional impairment while a score between 10 and 20 represents
functional impairment but less severe clinical symptomology. The
cutoff score between clinical and non-clinical populations lies at 10.
Cronbach’s alpha at baseline = 0.85.
Treatment retention
In this study, we defined dropout as less than or equal to six months
of treatment, following the definition by Kvarstein and colleagues
(2015) and the definition of “early dropouts” by Bateman & Fonagy
(2009). In a study where the treatment duration is up to 36 months,
we considered greater than six months to be a reasonable measure
of dropout. Different MBT studies have varied in how they
operationalize dropout from greater than three months (Laurenssen
et al., 2013) to greater than two years (Jørgensen et al., 2013).
Statistical procedures
Linear mixed models (LMMs) were used for statistical analysis of the
longitudinal data (Singer & Willett, 2003). For psychotherapy
research, traditional data analytic techniques like Anova contain
restrictive assumptions of sphericity (equal error variance across
time points). They also utilize group means and variances and thus
have several problems with handling missing data. Missing data
have to be expected to some degree in naturalistic clinical settings,
and if therapy is assumed to be efficient, larger variability at the start
of the treatment is expected compared to the follow-up assessment
(Tasca & Gallop, 2009). Thus, LMMs are tailored for psychotherapy
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research data in naturalistic settings, because doing so does not
require data to meet the sphericity assumption. At the same time, it
allows individuals to have different waves of data. The primary
outcome data were measured at start of treatment and at follow-up
(two timepoints); those were number of SCID-II PD traits, number of
SCID-II borderline traits, and number of SUD diagnoses. The
longitudinal secondary outcome data with 12 timepoints consisted of
CIP, GAF, WSAS, GSI, and RSES. We performed a visual
inspection of the data to determine whether a linear or nonlinear
model best fitted the data and found that a linear model was a good
fit. Time was modeled as a continuous variable with 6-month
intervals and with baseline as time zero. Due to a low number of N,
we allowed only random effects at baseline and kept the change
over time as a fixed effect. Random effects at baseline imply that we
allow the intercept to vary across individuals, and by keeping the
slope as a fixed effect, we estimate the mean change over time
across individuals. Due to a large amount of missing data across
patients and measurement occasions, we imputed 20 data sets
using the R package “mitml,” or “Tools for Multiple Imputation in
Multilevel Modeling” (Grund, Robitzsch, & Lüdtke, 2017). We used
the default inverse-Wishart priors, which give the minimum degrees
of freedom with the largest dispersion. Furthermore, we used 50,000
burn-ins, 10,000 iterations apart. Estimates and standard errors
were aggregated across the multiple imputed data sets (Barnard &
Rubin, 1999), adjusting for smaller sample sizes using 28 degrees of
freedom.
We calculated effect sizes’ pseudo R  using the bivariate correlation
between predicated scores and observed scores. We then
transformed R  to Cohen’s d through the formula d = 2r/√ (1 – r ) for
pedagogical interpretative purposes. Analyses were performed with
IBM 2015 SPSS statistics 23 and the R version 3.4.2 (2017, The R
Foundation for Statistical Computing).
Patient consent
All patients received written information that explained the purpose
of the study and allowed them to withdraw at any time. All the
participants gave their written consent. The study was approved by
the Regional Ethical Committee West (REK vest) for medical
research in Norway. 
Results
Primary outcome: Substance use and personality disorder
Axis I SUD diagnosis
At baseline, patients (N = 18) had a predicted mean of 1.78 (SE =
0.20) SUD diagnoses, and at follow-up, they had a predicted mean




to follow-up on SUD diagnosis was highly significant at the two-tailed
level (t(28) = ‑6.26, p < .001). The effect size was very large (d =
2.12).
SCID-II personality traits
Prior to MBT, patients had a predicted mean of 17.72 (SE = 1.97)
PD traits. At follow-up PD traits had declined to a predicted mean of
7.89 (SE = 1.83). The difference was highly significant at the two-
tailed level (t(28) = ‑3.71, p = .001). The effect size was large (d =
1.31).
Borderline traits
At start of treatment, patients (N = 18) had a predicted mean of 5.39
(SE = 0.45) borderline traits according to the SCID-II interview. At
follow-up the patients’ predicted mean of borderline traits had
declined to 2.00 (SE = 0.43). The change from baseline to follow-up
was highly significant at the two-tailed level (t(28) = ‑6.24, p < .001).
The effect size was very large (d = 1.94). Only two out of 13 patients
still fulfilled the criteria for BPD (five and six traits) at follow-up.
Secondary outcome measures
Symptom distress
At baseline, patients had a predicted mean GSI of 1.25 (SE = 0.14).
Their GSI declined to a predicted mean of 0.57 (SE = 0.07) at
follow-up. Change over time for GSI was significant (t(28) = ‑2.93, p
= .028). The effect size was large (d = 1.18). The predicted mean
change per six months was ‑0.06 (SE = 0.02). Nine out of 13
patients were below the clinical cutoff at follow-up assessment (GSI
≤ 0.8).
Interpersonal functioning
At baseline, the predicted mean of CIP was 1.28 (SE = 0.10). It
decreased to a predicted mean of 0.90 (SE = 0.07) at follow-up.
Effect size for change over time in CIP was moderate (d = 0.71) and
change from baseline to follow-up was near significant (t(28) =
‑2.26, p = .073). The predicted mean change per six months was
‑0.03 (SE = 0.02). Concerning the clinical cutoff (0.8), six out of 13
patients were below or equal to that at follow-up assessment (CIP ≤
0.8).
Global assessment of functioning
At baseline, patients had a predicted mean of GAF at 46.89 (SE =
2.15). At follow-up, their predicted GAF score had increased to 67.81
(SE = 1.00). Change over time for GAF was significant (t(28) = 4.64,
p = .004) and the change rate per six months was 1.90 (SE = 0.41).
The effect size was large (d = 2.06). Looking at the clinical cutoff
with a GAF score above the level of 60, 10 out of 13 patients were
assessed to be higher or equal to 60 at follow-up.
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Self-esteem
RSES at start of treatment had a predicted mean of 2.34 (SE =
0.15). This figure increased to a predicted mean of 3.06 (SE = 0.10)
at follow-up. Change over time for RSES was significant (t(28) =
3.34, p = .012) and the change rate per six months was 0.07 (SE =
0.02). The effect size for change until follow-up was large (d = 0.96).
Looking at the clinical cutoff, defined as ranging from 2.6 to 3.4, only
three patients were within the range of normal self-esteem at follow-
up. Eight patients scored lower than the lower cutoff of 2.6, and two
patients scored higher than the upper cutoff of 3.4.
Work functioning
WSAS at start of treatment had a predicted mean of 18.71 (SE =
1.74), and at follow-up the predicted mean of WSAS had dropped to
3.79 (SE = 0.73). For WSAS, the change over 5.5 years was also
highly significant (t(28) = ‑4.13, p =.006) and the change rate per six
months was ‑1.36 (SE = 0.33). The effect size for change until
follow-up was large (d = 1.87). In WSAS, the cutoff score between
clinical and non-clinical populations lies at 10, and nine out of 13
patients were equal to or below that cutoff score. The remaining four
patients were all within the range of 10–20, suggesting functional
impairment but less severe clinical symptomology.
TABLE 4: Longitudinal outcomes baseline to follow-up.
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FIGURES 2‑6: These figures demonstrate predicted longitudinal trajectories of
change based on linear mixed model estimates of secondary outcome variables.
The solid line demonstrates the predicted values; shadowed area represents the
95% upper and lower confidence intervals. For clinical interpretation the clinical
cut-off line has also been added to the charts at the y-axis.
Treatment retention
Four out of 18 patients (22%) were defined as dropouts (≤ six
months in therapy). Five patients did not attend to the follow-up
assessment for various reasons, which included saying no, being
unavailable, discontentment with therapists, avoiding the
appointments, serious injured to one patient after a drug-related
accident.
Discussion
The aim of the present study was to investigate whether patients
with BPD/SUD could benefit from participating in a specialized
treatment, MBT, developed for patients with BPD. Our research
questions were: 1) did participants improve on substance use
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disorder and 2) did they enter a positive trajectory regarding their
BPD? Furthermore, we wanted to investigate participants’
improvements on secondary outcome measures: interpersonal
functioning, global functioning, social functioning, and symptom
severity. The main findings of our study were that patients with
BPD/SUD showed significant improvement on both primary and
secondary outcome measures. Effect sizes ranged from moderate to
very large, with most being large.
Substance use decline
This MBT pilot was tailored to deal with the comorbidity of BPD/SUD
since the trial happened within a specialized clinic for substance use
disorders and all therapists were trained in the treatment of
substance use disorder and personality disorder. Thus, a dual focus
on both core issues of PD together with a continuous focus on
substance use and how to reduce it were imminent during the whole
treatment trajectory. Therapists probably also tolerated better (dealt
with their countertransference), because of their experience and
training, the hardcore realities of patients living in the peripheral life
situations of drug and alcohol addiction.
The use of an MBT-oriented social counselor and the focus both
psycho-pedagogically and therapeutically on substance use and its
relation to mentalizing are somewhat different from how MBT is
delivered in other settings. For example, the specific focus on
exploring mentalizing failure prior to substance intake is an
intervention that needs to be utilized when working with BPD/SUD
patients. Our pilot also offered 36 months of treatment as opposed
to the original authors who suggest 18 to 24 months (Bateman &
Fonagy, 2016). The present study is performed as a pilot, and we
had no randomization or control group. Conclusions must be taken
with great care. Still, we found our results regarding SUD intriguing.
To our surprise, many of the patients achieved full remission of their
SUD. Several of them had long histories with outpatient and inpatient
treatment in our own institution and thus were in danger of being
viewed upon as chronic patients. We believe that the model of
primacy of PD in the etiology of PD/SUD is of interest (Vélez-
Moreno et al., 2016; Verheul & van den Brink, 2005). In this pilot, the
focus was on increasing patients’ ability to mentalize (an issue
related to their PD symptomology), especially during moments of
emotional activation and attachment-related arousal. In MBT, this
focus is systematic and continues throughout the whole clinical
trajectory.
It seems that by targeting BPD-related problems, there is an effect
on SUD for these patients. Other inpatient and outpatient treatments
had not achieved these results before. In some studies on Nordic
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SUD patients (with high prevalence of PD), the remission of SUD at
five- and six-year follow-up after treatment is not that encouraging,
with relapse rates at 70% (Landheim et al., 2006) and 54% (Fridell &
Hesse, 2006). We performed a two-year follow-up and thus cannot
directly compare our findings to the studies above. In another
longitudinal study, disappearance of BPD coincided with the
disappearance of SUD (Paris & Zweig-Frank, 2001). This tendency
converges with our findings where SUD and BPD both demonstrated
substantial decline from baseline to follow-up. It also supports the
notion that by focusing on BPD-related difficulties through increasing
the ability of mentalizing (Philips et al., 2012), there is a possible
effect on SUD as well (Outcalt et al., 2016). But there are some who
have advocated that SUD must be seen as a chronic disorder and
that treatment needs to shift focus from curing the disorder to
symptom relief (McLellan, 2002). Our findings contradict this
perspective and give a tentatively more positive view on SUD (and
comorbid PD). There is perhaps a possibility of treating both
disorders, given targeted treatments.
Reduction of borderline symptomology
MBT is a tailored treatment for BPD (Bateman & Fonagy, 2016), and
assessing whether patients still have BPD after completion of
treatment is thus important. In our study, both the number of
personality disorder criteria declined, and the diagnosis of BPD
disappeared at follow-up. This is quite encouraging with respect to
the efficiency of MBT with this dual diagnosis patient group, and it
supports the notion that MBT is increasingly efficient in line with the
severity of the patient group pathology (Bateman & Fonagy, 2013).
Two patients still fulfilled the criteria for BPD at follow-up. These
patients deserve detailed case studies. The decline in both
borderline personality disorder and substance use disorder during
the same clinical trajectory supports the notion that PD and SUD are
connected and causally connected to each other in some way. Three
models have been proposed on the interconnectedness of PD/SUD,
and most support lies with the model where PD is primary to SUD
(Verheul & van den Brink, 2005).
Improvement in social functioning, self-esteem, and
symptomatic distress
Overall the results on our secondary outcome measures
demonstrate improvement. For all our outcome measures except for
interpersonal functioning, the predicted trajectories lie within the non-
clinical domain at follow-up. On self-esteem, symptom distress,
general functioning, and work and social functioning, patients reach
non-clinical levels. These results are quite encouraging.
Interpersonal functioning does significantly change from baseline to
follow-up but does not at any point reach non-clinical levels. Treating
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dual diagnosis patients with comorbid personality disorder is
challenging. We are just getting started in gaining enough
knowledge on what these patients need for positive change
trajectories. Many of our patients in this pilot reached symptomatic
improvement and remission of SUD and PD. Further follow-up
studies need to be performed to investigate if these changes endure
in the longitudinal trajectory of MBT patients.
Do BPD/SUD patients have unique trajectories regarding
GSI and CIP?
Do they get worse before they get better? Our sample of dual
diagnosis patients reported lower symptom distress on the GSI at
baseline than patients with BPD alone; see for instance Bateman &
Fonagy (2009), Kvarstein et al. (2015), and Laurenssen et al.
(2013). GSI in these studies were respectively 2.0, 2.1, and 2.2
versus our sample who reported predicted baseline levels of GSI to
be 1.3. The one MBT study that had a sample of BPD patients
where 79% had comorbid SUD also demonstrated their baseline
symptom distress scores to be somewhat lower than the studies
above, at 1.7 (Bales et al., 2012).
The patients in our sample also had lower CIP sum scores on
baseline (1.3) than other studies with borderline personality disorder
(2.0, 1.7) (Bateman & Fonagy, 2009; Kvarstein et al., 2015). We
think this tendency demonstrates how SUD intervenes with the
subjective experience of interpersonal problems and symptom
distress. Substance use has been suggested to function as a
regulator of emotional activation, particularly during moments of an
activated attachment system (Philips et al., 2012). This hypothesis
converges with theories in the field where substance use has been
suggested to potently interfere with attachment needs (Cihan,
Winstead, Laulis, & Feit, 2014; Insel, 2003). This gives indices that
the psychotherapeutic trajectory for BPD/SUD patients could
possibly involve a worsening of the subjective experience of
symptom severity and interpersonal functioning when and if their
substance use declines. These nonlinear change trajectories were
not possible to model in this study due to a low number of n.
The reasons for these discrepancies between BPD/SUD patients
and BPD alone are unknown and require further empirical
investigation. We speculate the following: 1) substance use has an
effect on the subjective experience of symptom distress and
interpersonal functioning and 2) BPD/SUD patients have unique
trajectories during psychotherapy on symptom distress and
interpersonal functioning.
Further studies are needed to investigate these hypotheses on the
uniqueness of BPD/SUD trajectories of change in psychotherapy.
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Treatment retention
Dropout in the treatment of BPD/SUD group of patients is a common
problem (Ball et al., 2006; Brorson et al., 2013). Therapeutic alliance
can be a challenge for SUD patients with Cluster B traits (Olesek et
al., 2016). Defining dropout as equal to or less than six months of
treatment, we had in our study four out of 18 patients dropping out
(22%). Our dropout rate is lower than numbers reported from other
studies with dual diagnosis patients. In dual diagnosis DBT studies,
the dropout rates have ranged from 36% to 55% (Axelrod,
Perepletchikova, Holtzman, & Sinha, 2011; Linehan et al., 2002;
Linehan et al., 1999). In MBT studies with BPD alone, the dropout
rate has varied from 5% to 43% (Jørgensen et al., 2013; Kvarstein
et al., 2015).
The problem is that the respective studies above do not define
dropout equally. Our dropout definition is equivalent to Kvarstein and
colleagues (2015) (5%), and it seems that compared with them, our
dropout rate is too high. Nevertheless, a dropout rate of 22% is
acceptable with a patient group known for problems with alliance
and treatment retention. We suggest, however, that further empirical
investigations would shed light on the reasons for dropout in this
patient group, so that we could better tailor our treatment programs.
Strength and limitations
There are several problems with this study, which implies that the
conclusions should be taken with great care. First, the study did not
involve any control group or randomization. Thus, we cannot
conclude that the changes these patients underwent were caused by
the actual treatment. In the natural trajectory of BPD patients,
symptomatic and personality distress does improve with the
passage of time (Gunderson et al., 2011; Zanarini, Frankenburg,
Hennen, & Silk, 2003). However, these patients’ social functioning is
less amenable to improvement and the prognosis is worse when
combined with SUD (Fridell & Hesse, 2006; Walter et al., 2009).
Second, the number of patients was very small, as is often a
problem in treatment studies of BPD/SUD patients. The statistical
analyses were limited by the small n, and the only analyses we could
perform were to substantiate that changes had occurred. Nonlinear
change trajectories could not be investigated, and comparisons
between different subgroups in the sample were not possible (e.g.,
dropouts vs. treated patients).
Third, we did not have any endpoint data on five patients. A full data
set might have influenced the results in a negative manner. The
response of some participants to our request might indicate that they
still have significant personality problems. The duration of their
treatments was also lower than our follow-up completers. We would
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also like to mention that supervisors and trainers from the
Norwegian Institute of Mentalizing were involved, which could
generate a positive bias. However, the most obvious contribution of
these trainers and supervisors was to secure adherence to and the
quality of the treatment that was delivered.
Finally, the diagnostics of the primary outcome measures and GAF
at follow-up was performed by the first and fourth author together.
The lack of blinding and investment in the study could bias the
results.
A considerable strength of the study was its ecological validity (i.e.,
that it was conducted in a clinical naturalistic setting). It is also
noteworthy that all patients had multiple experiences with former
treatments, both inpatient and outpatient treatments, and most of
them from the same clinic where this pilot was performed. Earlier
treatment had not had any lasting effect on their personality disorder
or SUD.
Conclusion
Patients suffering from both severe personality disorder of the
borderline type and substance abuse are known to be difficult to
treat and have a very poor prognosis. Our study indicates that MBT
might be a promising treatment modality for this comorbid condition.
We found that for the majority of the patients, their drug and alcohol
consumption and personality problems improved considerably.
However, the results for the cohort as a whole are somewhat
uncertain since 28% of the patients did not respond to follow-up.
Furthermore, because this was a feasibility study, our findings
indicate that MBT is implementable in a drug clinic, that clinicians
and patients find the treatment protocol acceptable, and that data
can be routinely collected. These favorable results indeed call for a
larger randomized study. 
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Abstract
Mentalization-based treatment for female patients with
comorbid personality disorder and substance use
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disorder: A pilot study
Objectives: In this study, we investigated the feasibility of
mentalization-based treatment (MBT) for patients with comorbid
substance use disorder (SUD) and borderline personality disorder
(BPD). No published study has ever specifically looked at MBT for
these patients. Such individuals are known to have a very poor
prognosis and harbor much pain and misery. Moreover, few
randomized controlled trials exist on psychotherapy efficiency for
patients with comorbid substance use disorder and borderline
personality disorder. There is an urgent need for more knowledge on
treatment for this patient group.
Design: A pilot project within a naturalistic clinical setting with
longitudinal data collection during treatment and at follow-up.
Eighteen female patients attended a pilot project and participated in
up to 36 months of treatment, according to the manuals. Patients
were measured on primary (pre/post) and secondary (longitudinal)
outcome measures before treatment, every six months during
treatment, at the end of treatment, and at follow-up approximately
two years after treatment.
Methods: Statistical analyses of repeated outcome measures (GSI,
CIP, GAF, WSAS, and RSES) and of pre/post measures (Axis I and
II diagnosis) were performed with linear mixed models, and Cohens
d was calculated. 
Results: Significant improvements on primary and secondary
outcome measures were demonstrated, with effect sizes ranging
from moderate to large. With respect to primary outcome, these
SUD/PD patients were almost fully recovered from their SUD at
follow-up (a predicted score of 0.2 Axis I SUD diagnosis at follow-up
in comparison with a score of 1.8 at baseline). 
Conclusion: MBT as performed in this pilot project indicates
promising results for patients with (mostly borderline) PDs and
comorbid SUDs. Performing RCT studies is warranted.
Keywords: borderline personality disorder, linear mixed models,
mentalization, pilot study, psychotherapy, substance use disorder.
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